 |
      
|
|
|
|
|
|||||
|
|
April 13, 2004
Neurochem invited to present findings on Alzheimer drug to Springfield Conference. About Neurochem's Presentations during the Symposium
Dr.Francine Gervais, Ph.D., Neurochem's Vice-President, Research and Development, will present the
Company's Glycosaminoglycan (GAG) Mimetic technology platform and explain how it would prevent the
formation of amyloid fibrils in the brain. She will also describe how in the three-month randomized
Phase II clinical trial, Neurochem's product candidate, Alzhemed™, was found to markedly reduce
the concentration of amyloid ß (Aß) protein in the cerebrospinal fluid of treated
patients in a dose-dependent fashion. Dr. Gervais' presentation will be made on Saturday, April 17,
2h10 P.M. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products
addresses critical unmet medical needs. Fibrillex™, designated as an orphan drug and as Fast
Track Product candidate, is in a Phase II/III clinical trial for the treatment of AA amyloidosis.
Alzhemed™ and Cerebril™ have completed a Phase II clinical trial for the treatment of
Alzheimer's disease and for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy
respectively. For additional information on Neurochem, please visit our website at: (www.neurochem.com).
Certain statements contained in this news release, other than statements of fact that are independently
verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as
they are on the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include
but are not limited to: the impact of general economic conditions, general conditions in the
pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which
Neurochem does business, stock market volatility, fluctuations in costs, and changes to the
competitive environment due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. The reader should not place undue reliance on the
forward-looking statements included in this news release. These statements speak only as of the
date made and Neurochem is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
